Combined medicine for treating pancreatic cancer and application thereof

The invention discloses a combined medicine for treating pancreatic cancer and application thereof. The combined medicine is prepared from low-dose naltrexone and an anti-PD-1 medicine or an anti-PD-L1 medicine, the application refers to the application of the combined medicine in preparation of a preparation for treating pancreatic cancer. Research results show that through the synergistic interaction of low-dose naltrexone (LDN) and anti-PD-1 drugs or anti-PD-L1 drugs, the immune level of tumor cells can be enhanced, the tumor environment can be improved, and the immune cell infiltration level of the tumor can be improved, so that the pancreatic cancer can be well inhibited, and a new way is provided for treatment of the pancreatic cancer. 本发明公开了一种治疗胰腺癌的联用药物及其应用。所述联用药物，包括低剂量纳曲酮与抗PD-1药物或抗PD-L1药物；所述应用为所述联合药物在制备治疗胰腺癌制剂中的应用。本发明研究结果表明低剂量纳曲酮(LDN)与抗PD-1药物或抗PD-L1药物的协同增效作用，可增强肿瘤细胞的免疫水平、改善肿瘤为环境、提高肿瘤免疫细胞浸润水平，从而发挥较好的抑制胰腺癌，为胰腺癌的治疗提供了一种新的途径。